Barclays raises Monopar Therapeutics price target to $145
Barclays raised its price target for Monopar Therapeutics to $145.00 per share from $128.00, keeping a maintained Overweight rating ().
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.